Progressive retinal degeneration of rods and cones in a Bardet-Biedl syndrome type 10 mouse model.
Sara K MayerJacintha ThomasMegan HelmsAishwarya KothapalliIoana CherascuAdisa SalesevicElliot StalterKai WangPoppy DattaCharles C SearbySeongjin SeoYing HsuSajag BhattaraiVal C SheffieldArlene V DrackPublished in: Disease models & mechanisms (2022)
Bardet-Biedl syndrome (BBS) is a multi-organ autosomal-recessive disorder caused by mutations in at least 22 different genes. A constant feature is early-onset retinal degeneration leading to blindness. Among the most common forms is BBS type 10 (BBS10), which is caused by mutations in a gene encoding a chaperonin-like protein. To aid in developing treatments, we phenotyped a Bbs10 knockout (Bbs10-/-) mouse model. Analysis by optical coherence tomography (OCT), electroretinography (ERG) and a visually guided swim assay (VGSA) revealed a progressive degeneration (from P19 to 8 months of age) of the outer nuclear layer that is visible by OCT and histology. Cone ERG was absent from at least P30, at which time rod ERG was reduced to 74.4% of control levels; at 8 months, rod ERG was 2.3% of that of controls. VGSA demonstrated loss of functional vision at 9 months. These phenotypes progressed more rapidly than retinal degeneration in the Bbs1M390R/M390R knock-in mouse. This study defines endpoints for preclinical trials that can be utilized to detect a treatment effect in the Bbs10-/- mouse and extrapolated to human clinical trials.
Keyphrases
- optical coherence tomography
- diabetic retinopathy
- early onset
- mouse model
- optic nerve
- clinical trial
- multiple sclerosis
- late onset
- endothelial cells
- genome wide
- gene expression
- high throughput
- deep learning
- dna methylation
- randomized controlled trial
- transcription factor
- replacement therapy
- duchenne muscular dystrophy
- bioinformatics analysis